{"filings":[{"id":696876,"accession_number":"0001640334-26-000973","cik":1621221,"company_name":"ARTELO BIOSCIENCES, INC.","ticker":"ARTL","form_type":"8-K","filed_at":"2026-05-27T20:39:45+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Artelo Biosciences launches $6.53M ATM program; Craft Capital files FINRA claim for $880K","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Entered at-the-market offering agreement with H.C. Wainwright to sell up to $6.53M of common stock, with 3.0% commission.","Shelf registration (Form S-3) effective May 19, 2026; ATM prospectus supplement filed May 26, 2026.","Craft Capital Management filed FINRA arbitration claim alleging breach of right of first refusal; seeks $880K success fee, warrants valued at $880K, plus late fees.","Company terminated engagement with Craft on March 27, 2026 and closed private placement of ~$11M on March 30, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":3546980.352941177,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":470279,"accession_number":"0001640334-26-000903","cik":1621221,"company_name":"ARTELO BIOSCIENCES, INC.","ticker":"ARTL","form_type":"8-K","filed_at":"2026-05-15T20:00:27+00:00","items":["1.02"],"status":"ready","headline":"Artelo Biosciences terminates ATM offering agreement with R.F. Lafferty; minimal prior sales","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Termination notice issued May 11, 2026; effective May 18, 2026.","Agreement allowed up to $6.5M in common stock sales; only 50,858 shares sold for $451,527 gross proceeds.","ATM program was entered July 18, 2025 and never significantly utilized."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":3546980.352941177,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94138,"accession_number":"0001640334-26-000662","cik":1621221,"company_name":"ARTELO BIOSCIENCES, INC.","ticker":"ARTL","form_type":"8-K","filed_at":"2026-04-07T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Artelo Biosciences regains Nasdaq compliance; monitored for one year","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq confirmed compliance with Equity Rule (≥$2.5M stockholders' equity) and Annual Meeting Rule.","Subject to mandatory panel monitor through April 6, 2027; re-deficiency could trigger delisting.","CEO cites focus on ART27.13 (cancer cachexia) Phase 2 data, ART26.12 (neuropathic pain), and partnerships.","Common stock trades on Nasdaq under ticker ARTL."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3546980.352941177,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106298,"accession_number":"0001640334-26-000574","cik":1621221,"company_name":"ARTELO BIOSCIENCES, INC.","ticker":"ARTL","form_type":"8-K","filed_at":"2026-03-30T23:59:59+00:00","items":["1.01","3.02","7.01","8.01","9.01"],"status":"ready","headline":"Artelo Biosciences closes $11M private placement; expects to regain Nasdaq compliance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds $11.0M from sale of 3.19M common shares (or pre-funded warrants) and 6.38M common warrants at $3.45/unit.","Net proceeds of $10.03M to be used for working capital, corporate purposes, and repayment of bridge debt.","Common warrants exercisable at $3.20 for 5.5 years; potential additional proceeds of $20.4M if fully cash-exercised.","Proceeds push stockholders' equity above $2.5M threshold; company awaiting Nasdaq confirmation of compliance.","H.C. Wainwright acted as placement agent, receiving 8% cash fee plus warrants for 255,073 shares at $4.3125."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":3546980.352941177,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106297,"accession_number":"0001640334-26-000554","cik":1621221,"company_name":"ARTELO BIOSCIENCES, INC.","ticker":"ARTL","form_type":"8-K","filed_at":"2026-03-26T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"Artelo expands ART27.13 development for muscle preservation with GLP-1 therapies","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ART27.13 to be evaluated as companion therapy to prevent muscle loss in patients on GLP-1 receptor agonists for weight reduction.","Preclinical study initiated; provisional patent filed covering use of CB2 agonists with GLP-1 drugs.","Independent research validated ART27.13 as a superagonist among 17 clinically studied CB2 agonists.","Muscle protective effect observed in CAReS trial (cancer cachexia) and preclinical reversal of myotoxicity.","J.P. Morgan projects global incretin market to reach $200B by 2030; ~25M Americans on GLP-1 by 2030."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":3546980.352941177,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106296,"accession_number":"0001640334-26-000475","cik":1621221,"company_name":"ARTELO BIOSCIENCES, INC.","ticker":"ARTL","form_type":"8-K","filed_at":"2026-03-18T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Artelo Biosciences raises $310k via 12% bridge notes with default conversion feature","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued two 12% bridge notes totaling $350,300 principal ($237,300 Vanquish + $113,000 Boot) for net proceeds of $310,000 after $40,300 OID.","Notes mature Jan 15, 2027; company may prepay at any time with no penalty.","Upon default, notes can convert into common shares at the higher of $0.125 or 75% of the 10-day VWAP; conversion capped at 4.99% beneficial ownership per holder.","Proceeds used for general working capital; Company reimbursed Vanquish $10,000 in fees.","Securities issued under Regulation D, Section 4(a)(2); represented as accredited investors only."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":3546980.352941177,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106295,"accession_number":"0001640334-26-000461","cik":1621221,"company_name":"ARTELO BIOSCIENCES, INC.","ticker":"ARTL","form_type":"8-K","filed_at":"2026-03-17T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Artelo Biosciences completes 1-for-3 reverse split; FY2025 net loss $12.9M, going concern","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["1-for-3 reverse stock split effective March 10, 2026; shares reduced from 2.1M to ~708k.","FY2025 net loss of $12.9M, up from $9.8M in FY2024; accumulated deficit reaches $63M.","Cash and cash equivalents of $0.6M at Dec 2025; auditor includes going concern qualification.","Loss on debt extinguishment totaled $1.158M ($825k + $333k related party) in FY2025.","Convertible notes issued at 12% interest; total convertible debt of $609k at Dec 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3546980.352941177,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106294,"accession_number":"0001640334-26-000395","cik":1621221,"company_name":"ARTELO BIOSCIENCES, INC.","ticker":"ARTL","form_type":"8-K","filed_at":"2026-03-06T23:59:59+00:00","items":["3.03","5.03","8.01","9.01"],"status":"ready","headline":"Artelo Biosciences effects 1-for-3 reverse stock split effective March 10, 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse split ratio 1-for-3; outstanding shares reduced from 2,124,772 to ~708,258.","Effective at market open on March 10, 2026; new CUSIP 04301G706.","No fractional shares issued; holders otherwise entitled to fractional share receive one whole share.","All outstanding warrants and other derivatives adjust automatically per their terms.","Board approved without stockholder vote under Nevada Revised Statutes 78.207."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":3546980.352941177,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106293,"accession_number":"0001640334-26-000227","cik":1621221,"company_name":"ARTELO BIOSCIENCES, INC.","ticker":"ARTL","form_type":"8-K","filed_at":"2026-02-05T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Artelo enters up to $50M equity purchase facility with Square Gate; issues 292K commitment shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Equity Purchase Agreement with Square Gate provides up to $25M initially, expandable to $50M at company's option.","Company issued 292,398 commitment shares valued at $500,000 to Square Gate as consideration.","Purchase price set at 95% of lowest VWAP during valuation period (Regular Put) or lowest traded price (Intraday Put).","Regular Put capped at $500K or 30% of daily volume; Intraday Put limited to 4.99% of outstanding shares.","Registration statement must be filed within 30 days; facility runs until Jan 2029 or earlier termination."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":3546980.352941177,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106292,"accession_number":"0001640334-26-000221","cik":1621221,"company_name":"ARTELO BIOSCIENCES, INC.","ticker":"ARTL","form_type":"8-K","filed_at":"2026-02-05T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Artelo Biosciences gets Nasdaq panel exception to cure listing deficiencies by March 30","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Panel granted exception to regain compliance with $2.5M stockholders' equity rule by March 30, 2026.","Company held 2025 annual meeting on Jan 30, curing annual meeting rule deficiency previously cited by Nasdaq.","Company previously received delist determination in Nov 2025; hearing stayed action.","Company intends to take all reasonable measures to regain compliance, but no assurance of success.","Failure to demonstrate compliance by March 30 could result in delisting from Nasdaq."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":3546980.352941177,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106291,"accession_number":"0001640334-26-000181","cik":1621221,"company_name":"ARTELO BIOSCIENCES, INC.","ticker":"ARTL","form_type":"8-K","filed_at":"2026-01-30T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Artelo Biosciences reports reconvened annual meeting results; directors re-elected, say-on-pay and auditor ratified","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Quorum achieved with 1,017,816 of 2,018,746 outstanding shares (50.4%) at reconvened meeting on Jan 30, 2026.","Class II directors Douglas Blayney (248,985 votes for) and Connie Matsui (257,384) re-elected.","Advisory say-on-pay passed with 158,971 for, 126,089 against, 103,377 abstaining.","Ratification of Malone Bailey LLP as auditor for FY 2026 approved: 830,673 for, 85,078 against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":3546980.352941177,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106290,"accession_number":"0001640334-26-000109","cik":1621221,"company_name":"ARTELO BIOSCIENCES, INC.","ticker":"ARTL","form_type":"8-K","filed_at":"2026-01-16T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Artelo Biosciences receives Nasdaq delisting notice for missing annual meeting deadline","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified Artelo on Jan 14, 2026 of non-compliance with the Annual Meeting Rule (5620(a)).","Annual meeting adjourned from Dec 31, 2025 to Jan 30, 2026 due to insufficient quorum.","Non-compliance is an additional basis for delisting; company already under equity deficiency (Rule 5550(b)(1)).","Company will take measures to regain compliance; stock continues trading pending hearing panel decision.","No assurance that appeal of equity deficiency delisting determination will succeed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":3546980.352941177,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106289,"accession_number":"0001640334-26-000005","cik":1621221,"company_name":"ARTELO BIOSCIENCES, INC.","ticker":"ARTL","form_type":"8-K","filed_at":"2026-01-02T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Artelo Biosciences adjourns 2025 annual meeting due to insufficient quorum; reconvenes Jan 30, 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Annual meeting convened Dec 31, 2025 and adjourned without conducting business due to lack of quorum.","Meeting reconvenes virtually on Jan 30, 2026 at 8:00 a.m. PT; record date remains Dec 10, 2025.","Additional proposal to ratify appointment of Malone Bailey LLP as independent auditor for FY2026 will be added.","Proxies previously submitted will be voted unless revoked; no changes to other proposals."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":3546980.352941177,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122603,"accession_number":"0001640334-25-002210","cik":1621221,"company_name":"ARTELO BIOSCIENCES, INC.","ticker":"ARTL","form_type":"8-K","filed_at":"2025-11-25T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Artelo Biosciences receives Nasdaq delisting notice; plans to appeal","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received delist determination on Nov 19, 2025 for non-compliance with equity rule (min $2.5M stockholders' equity).","Submitted compliance plans on July 7 and Aug 29, 2025, but did not complete the planned capital raise.","Unless appeal requested by Nov 26, delisting effective Dec 1, 2025; intends to appeal to Nasdaq hearing panel.","Stock (ARTL) continues trading on Nasdaq during appeal process."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3546980.352941177,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122602,"accession_number":"0001640334-25-002118","cik":1621221,"company_name":"ARTELO BIOSCIENCES, INC.","ticker":"ARTL","form_type":"8-K","filed_at":"2025-11-14T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Artelo Biosciences amends bylaws to eliminate stockholder right to fill board vacancies, adopt plurality voting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Board amended bylaws on November 10, 2025, effective immediately.","Stockholders' right to fill board vacancies eliminated; board retains sole authority.","Directors will be elected by plurality of votes cast at stockholder meetings."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":3546980.352941177,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122601,"accession_number":"0001640334-25-001930","cik":1621221,"company_name":"ARTELO BIOSCIENCES, INC.","ticker":"ARTL","form_type":"8-K","filed_at":"2025-10-31T23:59:59+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"Artelo Biosciences issues $690K convertible notes and warrants to investors including directors","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued convertible notes aggregating $690,154.69 principal to investors, converting May 2025 notes.","Notes bear 12% interest (20% on default), mature ~April 28, 2026, convertible at $3.40/share.","Warrants to purchase 438,182 shares of common stock at $3.40 per share, exercisable for 5 years.","Directors Connie Matsui ($110,842), Tamara Favorito ($19,793), and CEO Gregory Gorgas ($27,710) participated."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":3546980.352941177,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122600,"accession_number":"0001640334-25-001880","cik":1621221,"company_name":"ARTELO BIOSCIENCES, INC.","ticker":"ARTL","form_type":"8-K","filed_at":"2025-10-27T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Artelo Biosciences appoints Mark Spring as CFO effective November 1, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Spring replaces Gregory Gorgas as principal financial officer and treasurer; Gorgas remains CEO.","Spring receives $250,000 base salary, 35% target bonus, and severance of 12 months base salary (18 months on change in control).","Gorgas amended agreement: severance increased to 24 months base salary and target bonus (36 months during CIC protection period).","Gorgas now eligible for severance on constructive termination outside CIC period; vesting provisions revised for post-Effective Date grants."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":3546980.352941177,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122599,"accession_number":"0001640334-25-001856","cik":1621221,"company_name":"ARTELO BIOSCIENCES, INC.","ticker":"ARTL","form_type":"8-K","filed_at":"2025-10-17T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Artelo Biosciences settles with activist investor Daniel Farb; he withdraws board nominations","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Daniel S. Farb and affiliates irrevocably withdraw director nominations for 2025 annual meeting (letter dated Sept 19, 2025).","Farb Group agrees to standstill, voting commitments in favor of Board nominees, and caps beneficial ownership at 8% of outstanding stock.","Mutual non-disparagement obligations and full mutual release of claims through date of agreement.","Company to reimburse Farb Group up to $90,000 for documented out-of-pocket expenses.","Farb gets opportunity to present value-creation ideas to Board at next regular or special meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":3546980.352941177,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122598,"accession_number":"0001640334-25-001766","cik":1621221,"company_name":"ARTELO BIOSCIENCES, INC.","ticker":"ARTL","form_type":"8-K","filed_at":"2025-10-01T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Artelo Biosciences closes $2M public offering of common stock and pre-funded warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds ~$2M from 441,210 shares at $4.40/share and 13,335 pre-funded warrants at $4.399/warrant (ex. price $0.001).","Underwriter R.F. Lafferty has 45-day option to purchase up to additional 68,181 shares/warrants for overallotments.","Net proceeds will advance preclinical/clinical development, manufacturing, and working capital needs.","Directors, officers subject to 30-day lock-up; company granted R.F. Lafferty right of first refusal through Dec 31, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":3546980.352941177,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139295,"accession_number":"0001640334-25-001680","cik":1621221,"company_name":"ARTELO BIOSCIENCES, INC.","ticker":"ARTL","form_type":"8-K","filed_at":"2025-09-15T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Artelo raises $0.25M from partial over-allotment exercise after $3M offering","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Underwriter exercised over-allotment option for 57,914 shares at $4.40/share, generating ~$0.25M gross proceeds.","Net proceeds to Artelo from the exercise are approximately $0.24M; closing occurred September 11, 2025.","The original underwritten offering of 640,924 shares and pre-funded warrants for $3M closed September 5, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":3546980.352941177,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139294,"accession_number":"0001640334-25-001660","cik":1621221,"company_name":"ARTELO BIOSCIENCES, INC.","ticker":"ARTL","form_type":"8-K","filed_at":"2025-09-10T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Artelo Biosciences amends bylaws; eliminates stockholder written consent, adopts Nevada control share provisions","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Board eliminated stockholders' right to act by written consent, effective immediately.","Bylaws updated to treat Artelo as Nevada 'issuing corporation' under NRS 78.378-78.3793.","Record date for shareholder meetings and dividends capped at 60 days prior to action.","Notice period for special board meetings revised; details in filed amendment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":3546980.352941177,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139293,"accession_number":"0001640334-25-001642","cik":1621221,"company_name":"ARTELO BIOSCIENCES, INC.","ticker":"ARTL","form_type":"8-K","filed_at":"2025-09-05T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Artelo Biosciences closes $3M public offering of common stock and pre-funded warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Closed underwritten offering of 640,924 shares at $4.40/share and 40,894 pre-funded warrants at $4.399 each.","Gross proceeds of ~$3.0 million; underwriter has 45-day option for an additional 102,272 shares.","Net proceeds to advance preclinical/clinical development of product candidates and for working capital.","R.F. Lafferty & Co. acted as sole book-running manager; offering closed on September 5, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":3546980.352941177,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139292,"accession_number":"0001640334-25-001617","cik":1621221,"company_name":"ARTELO BIOSCIENCES, INC.","ticker":"ARTL","form_type":"8-K","filed_at":"2025-09-03T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Artelo Biosciences reports positive interim Phase 2 data for ART27.13 in cancer cachexia; seeks licensing partner","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Interim Phase 2 CAReS: ART27.13 patients gained 6.38% mean body weight vs placebo loss of -5.42% at 12 weeks.","Lean body mass increased +4.23% in treatment group vs -3.15% loss in placebo at one month.","Safety: 22% of 32 patients had possibly related adverse events, all mild/moderate except one severe malaise; no drug-related serious AEs.","Company will not internally fund Phase 3; plans to pursue licensing/partnership for ART27.13 as most value-accretive path."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3546980.352941177,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139291,"accession_number":"0001640334-25-001613","cik":1621221,"company_name":"ARTELO BIOSCIENCES, INC.","ticker":"ARTL","form_type":"8-K","filed_at":"2025-08-29T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Artelo shareholders approve 60x increase in common stock authorization; preferred increase fails","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Common stock authorization increased from 8.3M to 500M shares; voted 325,388 For vs 38,731 Against.","Preferred stock authorization increase (69,444 to 10M) and blank-check authority rejected; 130,740 Against, 170,461 broker non-votes.","Ratification of Malone Bailey LLP as auditor for FY2025 approved: 338,395 For, 21,362 Against.","Special Meeting held August 28, 2025; 365,886 of 704,425 shares represented."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.15,"market_cap_usd":3546980.352941177,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139290,"accession_number":"0001640334-25-001570","cik":1621221,"company_name":"ARTELO BIOSCIENCES, INC.","ticker":"ARTL","form_type":"8-K","filed_at":"2025-08-20T23:59:59+00:00","items":["1.02","9.01"],"status":"ready","headline":"Artelo Biosciences terminates private placement and ABK Labs consulting pact","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Terminated Aug 1 Securities Purchase Agreement for 593,252 shares and 2,126,809 warrants; no securities issued.","Company will return any purchase price received and paid $50,000 legal fees; no termination penalties.","Terminated Consulting Agreement with ABK Labs effective Aug 16; forfeited warrant for 55,000 shares at $10.20.","Both agreements terminated with mutual releases; no cash payments for consulting termination."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":3546980.352941177,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139289,"accession_number":"0001640334-25-001375","cik":1621221,"company_name":"ARTELO BIOSCIENCES, INC.","ticker":"ARTL","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Artelo Biosciences Enters Consulting Agreement with ABK Labs for Digital Asset Strategy","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Artelo signed a 4-year consulting agreement with ABK Labs for strategic advisory on digital asset strategy, business development, and investor relations.","Company agreed to issue warrants to purchase 55,000 shares at $10.20 per share, subject to board approval and performance milestones.","Warrants vest in tranches based on continued service and achievement of market capitalization thresholds, with acceleration provisions.","ABK Labs will advise on digital asset allocation, partnerships, financial modeling, and communication of Artelo's digital asset strategy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":3546980.352941177,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139288,"accession_number":"0001640334-25-001334","cik":1621221,"company_name":"ARTELO BIOSCIENCES, INC.","ticker":"ARTL","form_type":"8-K","filed_at":"2025-08-04T23:59:59+00:00","items":["1.01","3.02","7.01","8.01","9.01"],"status":"ready","headline":"Artelo raises ~$9.5M private placement to buy Solana; gets UK MHRA nod for Phase 1 trial","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Gross proceeds ~$9.475M from 593,252 shares at $10.20 plus prefunded warrants; also issues Market Priced ($10.20) and $50.00 warrants.","Net proceeds from shares will be used to purchase SOL; warrant proceeds for working capital and additional SOL.","UK MHRA provided favorable guidance for first-in-human Phase 1 trial of ART12.11 (CBD:TMP cocrystal) for anxiety/depression.","Offering expected to close Aug 5, 2025; registration statement to be filed within 15 days of closing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":3546980.352941177,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139287,"accession_number":"0001640334-25-001240","cik":1621221,"company_name":"ARTELO BIOSCIENCES, INC.","ticker":"ARTL","form_type":"8-K","filed_at":"2025-07-18T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Artelo Biosciences enters $6.5M at-the-market equity offering with R.F. Lafferty","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Agreement with R.F. Lafferty & Co. to sell up to $6.5M of common stock via ATM program.","Manager commission: 2.0% of gross sales price per share; Company may set minimum price.","Offering can be suspended by either party on 5 days' notice; Company has no obligation to sell.","Based on existing Form S-3 shelf effective July 14, 2023; prospectus supplement filed July 18, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":3546980.352941177,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139286,"accession_number":"0001640334-25-001184","cik":1621221,"company_name":"ARTELO BIOSCIENCES, INC.","ticker":"ARTL","form_type":"8-K","filed_at":"2025-07-11T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Artelo Biosciences completes 1-for-6 reverse split; cash falls to $2.1M with negative working capital","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["1-for-6 reverse split effective June 13, 2025, reducing outstanding shares from 3,280,000 to ~546,667.","Authorized common shares cut from 50M to 8,333,333; preferred authorized reduced from 416,667 to 69,444.","Preliminary June 30, 2025 cash & equivalents ~$2.1M; working capital expected between -$1.2M and -$1.5M.","Company restates substantial doubt about going concern and continues to report recurring operating losses.","FY2024 net loss $9.8M (vs $9.3M in FY2023); accumulated deficit reached $50.1M at Dec 31, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":3546980.352941177,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156869,"accession_number":"0001640334-25-001062","cik":1621221,"company_name":"ARTELO BIOSCIENCES, INC.","ticker":"ARTL","form_type":"8-K","filed_at":"2025-06-26T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"Artelo raises $1.425M in private placement; to use $250k proceeds to buy SOL","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds ~$1.425M from private placement of shares, pre-funded warrants, and warrants.","Issuing 136,844 shares, 93,179 pre-funded warrants, plus warrants for 460,046 shares at $5.82 and 230,023 at $10.00.","$250k of net proceeds to purchase SOL cryptocurrency; balance for general corporate and clinical data announcements.","Closing expected June 26, 2025; company to file resale registration statement within 15 days."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":3546980.352941177,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156868,"accession_number":"0001640334-25-001046","cik":1621221,"company_name":"ARTELO BIOSCIENCES, INC.","ticker":"ARTL","form_type":"8-K","filed_at":"2025-06-13T23:59:59+00:00","items":["3.03","5.03","8.01","9.01"],"status":"ready","headline":"Artelo Biosciences completes 1-for-6 reverse stock split; Nasdaq compliance regained","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Effective 12:01 a.m. ET June 13, 2025; each 6 pre-split shares combine into 1 post-split share; outstanding shares reduced from 3,280,000 to ~546,667.","Authorized common shares reduced from 50M to 8,333,333; preferred authorized reduced from 416,667 to 69,444.","New CUSIP: 04301G607. No fractional shares; holders receive one whole share for any fractional entitlement.","Warrants adjust: each 6 pre-split warrants (exercise $0.75) combine into 1 warrant exercisable at $4.50 per post-split share.","Nasdaq confirmed on June 13, 2025 that ARTL regained compliance with the $1.00 minimum bid price requirement; deficiency matter closed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":3546980.352941177,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156867,"accession_number":"0001640334-25-000935","cik":1621221,"company_name":"ARTELO BIOSCIENCES, INC.","ticker":"ARTL","form_type":"8-K","filed_at":"2025-05-23T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Artelo Biosciences notified by Nasdaq of equity deficiency; $652K vs $2.5M minimum","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["As of March 31, 2025, stockholders' equity was $652,000, below the $2.5M minimum required by Nasdaq Rule 5550(b)(1).","Company has 45 days (until July 7, 2025) to submit a compliance plan to Nasdaq.","If plan accepted, Nasdaq may grant up to 180 days (until Nov 18, 2025) to evidence compliance.","No immediate impact on listing; common stock continues trading on Nasdaq pending review.","Company evaluating options; no assurance that compliance plan will be accepted or delisting avoided."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3546980.352941177,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156866,"accession_number":"0001640334-25-000732","cik":1621221,"company_name":"ARTELO BIOSCIENCES, INC.","ticker":"ARTL","form_type":"8-K","filed_at":"2025-05-01T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Artelo Biosciences raises $900k via convertible notes with 12% interest and warrants","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Closed $900,000 convertible note offering; directors and management purchased $200,000 of the notes.","Notes carry 12% annual interest (20% on default), mature in 180 days; voluntary conversion at $1.29/share.","Unconverted principal automatically converts to warrants at $0.125/share; exercise price $1.04/share.","Warrants have 5-year term, cashless exercise option, and standard anti-dilution provisions.","Company commits to file resale registration statement for underlying shares within 45 days after maturity."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":3546980.352941177,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156865,"accession_number":"0001640334-25-000719","cik":1621221,"company_name":"ARTELO BIOSCIENCES, INC.","ticker":"ARTL","form_type":"8-K","filed_at":"2025-04-29T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Artelo Biosciences receives Nasdaq minimum bid price deficiency notice; 180-day cure period until Oct 20, 2025","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq notice on April 23, 2025 for non-compliance with $1.00 minimum bid price requirement.","Must regain compliance by Oct 20, 2025; closing bid price must meet or exceed $1.00 for 10 consecutive business days.","Possible second 180-day extension if other listing standards met; company may implement a reverse stock split.","No immediate effect on listing; company intends to monitor bid price and evaluate available options."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3546980.352941177,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192214,"accession_number":"0001640334-24-001915","cik":1621221,"company_name":"ARTELO BIOSCIENCES, INC.","ticker":"ARTL","form_type":"8-K","filed_at":"2024-12-20T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Artelo Biosciences announces annual meeting results; re-elects directors and ratifies auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["40.9% of shares represented at Dec 20, 2024 annual meeting (1,319,986 of 3,227,700 outstanding).","Directors Steven Kelly and R. Martin Emanuele re-elected to Class I board seats until 2027.","Ratification of Malone Bailey LLP as independent auditor for FY ending Dec 31, 2024 (1,258,378 for, 57,083 against)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":3546980.352941177,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}